Endocrine system

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

Wednesday, August 4, 2021 - 9:05pm

TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021. The Company also provided an update on its pre-clinical and clinical development programs.

Key Points: 
  • TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021.
  • In consultation with The University of Sheffield, UK, selected AEZS-150 as the lead candidate in the Company's delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program.
  • In February 2021, Aeterna entered into an exclusive option agreement with Julius-Maximilians-University to evaluate a preclinical, potential COVID-19 vaccine developed at Julius-Maximilians-University.
  • The Company had $69.9 million cash and cash equivalents at June 30, 2021 (March 31, 2021 73.4 million).

HealthLynked Corp. Announces the Addition of Sabrina Katz as Multimedia Executive Producer and Spokesperson

Thursday, July 29, 2021 - 1:00pm

Miss Katz will oversee creating a wide range of educational, informative, and unique video content for HealthLynked.

Key Points: 
  • Miss Katz will oversee creating a wide range of educational, informative, and unique video content for HealthLynked.
  • News segments will feature common health issues starting with women's healthcare covering menopause, hormone replacement therapies, breast cancer, cervical dysplasia and more.
  • "We are excited to have Sabrina join HealthLynked as our multimedia producer and company spokesperson.
  • For additional information about HealthLynked Corp., please visit www.healthlynked.com and connect with HealthLynked on Twitter, Facebook, and LinkedIn.

Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12

Tuesday, July 27, 2021 - 9:01pm

About Aspira Womens Health Inc.

Key Points: 
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
  • OVA1 plus includes our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses.
  • With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research.

Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

Monday, July 26, 2021 - 12:00pm

I am excited that patients are now being enrolled in this study and that TRV027 is the one of the first active treatment arms available for patient randomization.

Key Points: 
  • I am excited that patients are now being enrolled in this study and that TRV027 is the one of the first active treatment arms available for patient randomization.
  • The trial, known as ACTIV-4 Host Tissue, is testing four investigational agents that combat dysregulation of the renin-angiotensin-aldosterone system (RAAS) and the immune system caused by a COVID-19 infection.
  • The trial is enrolling approximately 1,600 patients at over 50 sites in the U.S. TRV027 is part of the initial trial launch, and additional study arms will be added to the trial over time.
  • I am very pleased that we have enrolled our first patient in the ACTIV-4 Host Tissue trial, and I look forward to investigating the potential of TRV027 to modulate the RAAS and improve outcomes for patients hospitalized with COVID-19.

Dr. Gerald Shulman Joins Levels as Advisor

Thursday, July 22, 2021 - 6:13pm

Levels , the first biowearable system to give real-time biofeedback on nutrition and lifestyle, today announced that Dr. Gerald Shulman, MD-PhD, has joined the company as an Advisor .

Key Points: 
  • Levels , the first biowearable system to give real-time biofeedback on nutrition and lifestyle, today announced that Dr. Gerald Shulman, MD-PhD, has joined the company as an Advisor .
  • In this role, Dr. Shulman will advise on our strategy and collaborate with Levels on research to understand better the physiologic drivers of insulin resistance and other metabolic dysfunction.
  • View the full release here: https://www.businesswire.com/news/home/20210722005815/en/
    Dr. Gerald Shulman Joins Levels as Advisor (Photo: Business Wire)
    Dr. Shulman is the George R. Cowgill Professor of Medicine and Professor of Cellular and Molecular Physiology at Yale.
  • Levels is currently running a closed beta program focused on product development and has a waitlist of over 115,000 people.

$11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) - Industry Analysis Report and Forecasts - ResearchAndMarkets.com

Thursday, July 22, 2021 - 5:01pm

A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.

Key Points: 
  • A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.
  • By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible.
  • Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine.
  • There is a growing case of diabetes and an increasing geriatric population, which is boosting the regional rapid-acting insulin market.

Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab

Thursday, July 22, 2021 - 2:59pm

Support for conditional approval would be based on data from this phase 1 study and the existing data from Humanigens Phase 3 LIVE-AIR study.

Key Points: 
  • Support for conditional approval would be based on data from this phase 1 study and the existing data from Humanigens Phase 3 LIVE-AIR study.
  • We are hopeful that these data, alongside data generated in Korea by our partners, will allow for the use of lenzilumab in South Korea.
  • Like many countries, South Korea is experiencing rising number of COVID-19 cases, particularly due to the spread of the Delta variant.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

Monday, July 19, 2021 - 9:01pm

SAN DIEGO, July 19, 2021 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021.

Key Points: 
  • SAN DIEGO, July 19, 2021 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021.
  • Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
  • Participants can access the live conference call by dialing 866-952-8559 (US) or 785-424-1743 (International) using the conference ID: NBIX.
  • For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Monday, July 19, 2021 - 1:00pm

Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.

Key Points: 
  • Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.
  • Gvoke is indicated for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes ages 2 years and above.
  • The United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo (glucagon) injection on April 29, 2021.
  • Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

Thursday, July 15, 2021 - 2:00pm

These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.